Quick Answer
RIGEL PHARMACEUTICALS INC reported Net Income Loss of $367.02 million for the year ending 2025.
- RIGEL PHARMACEUTICALS INC showed an increase of +1,999.1% in Net Income Loss from 2024 to 2025.
- This data is from RIGEL PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: -$14.17 million | Q1 2021: $39.50 million | Q2 2021: -$13.82 million | Q3 2021: -$20.95 million | Q1 2022: -$27.45 million | Q2 2022: -$13.49 million | Q3 2022: -$19.04 million | Q1 2023: -$13.54 million | Q2 2023: -$6.60 million | Q3 2023: -$5.69 million | Q1 2024: -$8.25 million | Q2 2024: -$1.03 million | Q3 2024: $12.42 million | Q1 2025: $11.45 million | Q2 2025: $59.61 million | Q3 2025: $27.90 million.
- Over the full 7 years of available data (2019 to 2025), RIGEL PHARMACEUTICALS INC's Net Income Loss has grown by 648.7%.
- Historical annual values: Fiscal year 2025: $367.02 million | Fiscal year 2024: $17.49 million | Fiscal year 2023: -$25.09 million | Fiscal year 2022: -$58.57 million | Fiscal year 2021: -$17.91 million | Fiscal year 2020: -$29.74 million | Fiscal year 2019: -$66.89 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: